文献速递系统性红斑狼疮

系统性红斑狼疮患者接受贝利尤单抗治疗后达到缓解和低疾病活动度的比例:五项随机临床试验汇总数据的事后分析

Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
PubMed 文献 · Lancet Rheumatol · 2024-08-26

该事后分析汇总五项贝利尤单抗3期试验的3086例活动性、自身抗体阳性系统性红斑狼疮患者数据,比较贝利尤单抗联合标准治疗与安慰剂联合标准治疗。第52周时,贝利尤单抗组达到DORIS缓解的比例为8%(148/1869),安慰剂组为6%(68/1217),风险比1.51(95%CI 1.15-1.99;p=0.0055);达到LLDAS的比例分别为17%(322/1869)和10%(125/1217),风险比1.74(95%CI 1.44-2.12;p<0.0001)。

要点

  • 第52周DORIS缓解率贝利尤单抗组8% vs 安慰剂组6%,风险比1.51(95%CI 1.15-1.99;p=0.0055)。
  • 第52周LLDAS达标率贝利尤单抗组17% vs 安慰剂组10%,风险比1.74(95%CI 1.44-2.12;p<0.0001)。
  • 在泼尼松等效剂量>7.5 mg/日的患者中,贝利尤单抗与安慰剂组DORIS缓解无差异。

核心结论

  • 在活动性系统性红斑狼疮成人患者中,贝利尤单抗联合标准治疗在达到DORIS缓解(两组达标率均低)和LLDAS方面优于安慰剂联合标准治疗,DORIS缓解差异最早见于第28周,LLDAS差异最早见于第8周。

研究设计与样本

  • 整合事后分析,汇总五项贝利尤单抗3期试验(BLISS-76、BLISS-52、BLISS-NEA、BLISS-SC和EMBRACE)的数据,纳入活动性、自身抗体阳性系统性红斑狼疮患者。
  • 患者随机接受贝利尤单抗(静脉10 mg/kg每月或皮下200 mg每周)或安慰剂,均联合标准治疗;共分析3086例患者(贝利尤单抗组1869例,安慰剂组1217例)。
  • 从第4周到第52周每4周分析DORIS缓解和LLDAS比例,采用改良Poisson回归校正试验间变异,并在全部患者及按基线SLEDAI-2000评分、抗双链DNA阳性、低补体C3或C4水平、泼尼松等效剂量、抗疟药使用和种族划分的亚组中进行分析。

主要发现

  • 第52周DORIS缓解率贝利尤单抗组为8%(148/1869),安慰剂组为6%(68/1217),风险比1.51(95%CI 1.15-1.99;p=0.0055)。
  • 第52周LLDAS达标率贝利尤单抗组为17%(322/1869),安慰剂组为10%(125/1217),风险比1.74(95%CI 1.44-2.12;p<0.0001)。
  • 在所有提示高疾病活动的基线亚组中,第52周贝利尤单抗组DORIS缓解比例高于安慰剂组,但泼尼松等效剂量>7.5 mg/日的患者中贝利尤单抗与安慰剂组DORIS缓解无差异。
  • 从第44周起,在所有提示高疾病活动的基线亚组中贝利尤单抗组LLDAS比例显著高于安慰剂组,部分亚组更早出现差异,且差异维持至第52周。

关键数值与推荐

  • DORIS缓解定义为Definitions of Remission in SLE(DORIS)缓解标准。
  • LLDAS定义为lupus low disease activity state(LLDAS)标准。
  • 贝利尤单抗剂量为静脉10 mg/kg每月或皮下200 mg每周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disease remission or low disease activity are key treatment targets for patients with systemic lupus erythematosus (SLE). Pivotal trials of belimumab were conducted before the introduction of these targets. In this study, we aimed to pool data across trials to assess attainment of remission and low disease activity in a large, racially and culturally diverse patient population with SLE. METHODS: In this integrated post-hoc analysis, we pooled data from five phase 3 trials of belimumab (BLISS-76 [NCT00410384], BLISS-52 [NCT00424476], BLISS-NEA [NCT01345253], BLISS-SC [NCT01484496], and EMBRACE [NCT01632241]), in patients with active, autoantibody-positive SLE. Patients were randomly assigned to receive belimumab (10 mg/kg per month intravenously or 200 mg per week subcutaneously) or placebo, plus standard therapy. The proportion of patients with Definitions of Remission in SLE (DORIS) remission and lupus low disease activity state (LLDAS) were analysed every 4 weeks from week 4 to week 52 for belimumab versus placebo, using modified Poisson regression adjusted for trial variance, in all patients and in subgroups per baseline SLE Disease Activity Index-2000 score (<10 or ≥10); anti-double stranded DNA positivity (yes or no); low complement 3 (C3) or C4 levels (yes or no); anti-dsDNA positivity or low C3 or C4 levels (yes and no); prednisone-equivalent dose (≤7·5 mg per day or >7·5 mg per day); antimalarial use (yes or no); and by race (Black African ancestry or African American, Asian, Indigenous American, or White). FINDINGS: Data for 3086 patients (1869 in the belimumab group and 1217 in the placebo group) were analysed. 2913 (94%) of 3086 patients were women and 173 (6%) were men, and the median age was 36 years (IQR 28-45). The proportion of patients with DORIS remission was significantly higher in the belimumab group than the placebo group at weeks 28, 48, and 52 (week 52: 148 [8%] of 1869 participants vs 68 [6%] of 1217 participants; risk ratio 1·51 [95% CI 1·15-1·99]; p=0·0055). The proportion of patients who attained LLDAS was higher in the belimumab group than the placebo group at weeks 8, 24, 32-52 (week 52: 322 [17%] of 1869 participants vs 125 [10%] of 1217 participants; 1·74 [1·44-2·12]; p<0·0001). A higher proportion of patients had DORIS remission at week 52 in the belimumab group than the placebo group among all baseline subgroups denoting high disease activity, with the exception of those on a prednisone-equivalent dose higher than 7·5 mg per day in whom there was no difference for DORIS remission with belimumab versus placebo. The proportion of patients with LLDAS was significantly higher among patients in the belimuab group than those who received placebo from week 44 in all baseline subgroups denoting high disease activity or earlier in some subgroups, and the differences were maintained at week 52. INTERPRETATION: In adults with active SLE, belimumab plus standard therapy yielded greater benefit than placebo plus standard therapy in attaining DORIS remission (for which low rates were attained in both groups) and LLDAS, with differences observed as early as week 28 for DORIS remission and week 8 for LLDAS. FUNDING: Swedish Rheumatism Association, King Gustaf V's 80-year Foundation, Swedish Society of Medicine, Nyckelfonden, Professor Nanna Svartz Foundation, Ulla and Roland Gustafsson Foundation, Region Stockholm, and the Karolinska Institutet.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Parodis I, Lindblom J, Levy RA, et al. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials. Lancet Rheumatol. 2024. PMID: 39208825. doi:10.1016/S2665-9913(24)00162-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。